A Study To Compare Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Post-Herpetic Neuralgia
NCT00599638
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Male or female of non-childbearing potential
- Pain present for more than 3 months after healing of herpes zoster skin rash
- VAS score of >=40mm at screening and baseline visits
- Patients with pain conditions which might impair the assessment of postherpetic
neuralgia
- Skin conditions in the affected dermatome that could alter sensation other than
postherpetic neuralgia
- History or diagnosis of DSM IV major depressive disorder
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Anniston, Alabama
- Litchfield Park, Arizona
- Phoenix, Arizona
- Atlantis, Florida
- Clearwater, Florida
- Largo, Florida
- Miami, Florida
- Palm Beach Gardens, Florida
- Sunrise, Florida
- Tampa, Florida
- Topeka, Kansas
- Towson, Maryland
- N. Dartmouth, Massachusetts
- Ann Arbor, Michigan
- Edina, Minnesota
- St Louis, Missouri
- Asheville, North Carolina
- Cleveland, Ohio
- Dayton, Ohio
- Kettering, Ohio
- Altoona, Pennsylvania
- Duncansville, Pennsylvania
- Bryan, Texas
- Dallas, Texas
- Houston, Texas
- San Antonio, Texas
- Richmond, Virginia
- Vina del Mar, V Region
- Moscow,
- St. Petersburg,
- St. Petersburg,
- Yaroslavl,
- Cadiz,
- Madrid,
- Ourense,
- Sevilla,
- Valencia,
- Linkoping,
- Stockholm,
- Stockholm,
- Dnipropetrovsk,
- Donetsk,
- Kharkiv,
- Kharkiv,
- Kharkiv,
- Kyiv,
- Odessa,
- Simferopol,
- Bexhill on Sea, East Sussex
- Blackpool, Lancashire
- Weybridge, Surrey
- Solihull,
- Nagoya, Aichi
- Ichikawa, Chiba
- Urayasu, Chiba
- Kasuga, Fukuoka
- Kasuya-gun, Fukuoka
- Maebaru, Fukuoka
- Maebashi, Gunma
- Takasaki, Gunma
- Asahikawa, Hokkaido
- Sapporo, Hokkaido
- Akashi, Hyogo
- Amagasaki, Hyogo
- Himeji, Hyogo
- Kobe, Hyogo
- Nishinomiya, Hyogo
- Tsuchiura, Ibaraki
- Sagamihara, Kanagawa
- Yokohama, Kanagawa
- Sendai, Miyagi
- Beppu, Ohita
- Kishiwada, Osaka
- Takatsuki, Osaka
- Kawaguchi, Saitama
- Kitamoto, Saitama
- Tokorozawa, Saitama
- Adachi-ku, Tokyo
- Arakawa-ku, Tokyo
- Bunkyo-ku, Tokyo
- Edogawa-ku, Tokyo
- Mitaka, Tokyo
- Nakano-ku, Tokyo
- Shinagawa-ku, Tokyo
- Shinjuku-ku, Tokyo
- Suginami-ku, Tokyo
- Toshima-ku, Tokyo
- Fukuoka,
- Fukushima,
- Osaka,
- Saitama,
- Leesburg, Florida
- Lexington, Kentucky
- Raleigh, North Carolina
- Jekintown, Pennsylvania
- Senftenberg, A-3541
- Wien,
- Schwerin,
- Pretoria, Gauteng
- Paarl, Western Cape
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | A Study To Compare Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Post-Herpetic Neuralgia | |||
Official Title ICMJE | A Two Week Double-Blind Placebo-Controlled Crossover Study To Compare The Efficacy And Safety Of A Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Patients With Post-Herpetic Neuralgia | |||
Brief Summary | Pregabalin is an alpha-2 delta ligand approved for the treatment of neuropathic pain, however, not all patients will respond to this drug. This study will compare the efficacy of pregabalin when administered with an experimental drug PF-00489791, in patients with post-herpetic neuralgia. The efficacy of this combination will be compared to pregabalin alone. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 2 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment | |||
Condition ICMJE | Postherpetic Neuralgia | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Estimated Enrollment ICMJE | 130 | |||
Original Estimated Enrollment ICMJE | Same as current | |||
Actual Study Completion Date ICMJE | December 2008 | |||
Actual Primary Completion Date | December 2008 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00599638 | |||
Other Study ID Numbers ICMJE | B0261002 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Director, Clinical Trials Disclosure Group, Pfizer, Inc. | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | October 2009 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |